Symbiotec Pharmalab IPO: Rs 1,757 Cr Issue Opens Now
Symbiotec Pharmalab IPO launch with financial growth indicators.
Key Highlights
Symbiotec Pharmalab’s Rs 1,757 crore IPO is open! Subscriptions run Aug 24-27, 2026. Explore price band, lot size, and potential listing gains.
Symbiotec Pharmalab’s Rs 1,757 crore is now live, with subscriptions opening August 24, 2026, and closing August 27, 2026. This public issue includes both a fresh share offering and an offer-for-sale.
IPO Snapshot
- Total IPO Value: Rs 1,757 crore
- : Rs 150 crore (15 lakh shares)
- Offer-for-Sale (): Rs 1,607 crore (1.63 crore shares)
- : Rs 938 to Rs 988 per share
- : 15 shares
- Minimum Investment: Rs 14,820
The (GMP) for Symbiotec Pharmalab stood at Rs 409 per share on August 24, 2026. This suggests an estimated listing price of Rs 1,397.
This indicates a potential listing gain of approximately 41.40% over the upper price band. Allotment is anticipated for August 28, with listing on and slated for September 1.
FY26 Financials
Symbiotec Pharmalab reported strong performance in FY26. Total income increased by 15% to Rs 872.26 crore from Rs 755.98 crore in FY25.
Profit after tax () also saw a 14% rise during the same period.
- FY26 : Rs 872.26 crore (up 15%)
- FY26 Profit After Tax: Rs 109.9 crore (up 14%)
Proceeds from the fresh issue will go towards prepaying or repaying outstanding borrowings and for general corporate purposes. Funds from the OFS will be directed to the selling shareholders.
Established in 2002, Symbiotec Pharmalab manufactures Active Pharmaceutical Ingredients (APIs), nutritional ingredients, and specialty products for global markets.